Responses of the human alpha 7
nicotinic acetylcholine receptor (nAChR) in Xenopus laevis oocytes were quantified using two-
electrode voltage clamp in the presence of
barium (10 mM) to block secondary activation of Ca(2+)-dependent
chloride currents. The effect of (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)
isoxazole (ABT-418) and (2,4)-dimethoxybenzylidene
anabaseine (GTS-21), two potential compounds for the treatment of
Alzheimer's Disease, and of the
natural product (+/-)
epibatidine were compared to (-)
nicotine. (+/-)
Epibatidine acted as an agonist and was 64-fold more potent than (-)
nicotine (EC50s = 1.30 +/- 0.11 microM and 83 +/- 10 microM, respectively).
ABT-418 also was an agonist, 3-fold less potent and 75% as efficacious as (-)
nicotine (EC50 = 264 +/- 34 microM).
GTS-21, in contrast, inhibited the response to (-)
nicotine at concentrations < or = 10 microM and itself elicited only a small response at higher concentrations (12% of the (-)
nicotine response at 1 mM). Reversible blockade by
methyllycaconitine (10 nM) corroborated the responses as due to activation of alpha 7 nAChR. This represents the first characterization of human alpha 7 nAChR responses to these novel
nicotinic agonists.